# Akebia Therapeutics, Inc.: financial statements, quarterly

AKBA · Nasdaq · CIK 1517022 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/akba.md) · [Financials](/companies/akba/financials.md) · [Filings](/companies/akba/filings.md) · [Insiders](/companies/akba/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/akba/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [42.0](/filings/0001628280-24-045979.md) | [56.2 d](/filings/0001517022-26-000020.md) | [32.6](/filings/0001628280-25-023460.md) | [43.6](/filings/0001628280-25-038600.md) | [37.4](/filings/0001517022-25-000046.md) | [46.5 d](/filings/0001517022-26-000020.md) | [57.3](/filings/0001517022-26-000039.md) | [62.5](/filings/0001517022-26-000051.md) | [58.8](/filings/0001517022-25-000046.md) | [57.6 d](/filings/0001517022-26-000020.md) | [53.5](/filings/0001517022-26-000039.md) | [49.1](/filings/0001517022-26-000051.md) |
| Cost of revenue | $m | [18.0](/filings/0001628280-24-045979.md) | [18.7 d](/filings/0001517022-26-000020.md) | [11.6](/filings/0001628280-25-023460.md) | [17.0](/filings/0001628280-25-038600.md) | [14.2](/filings/0001517022-25-000046.md) | [20.4 d](/filings/0001517022-26-000020.md) | [7.6](/filings/0001517022-26-000039.md) | [9.9](/filings/0001517022-26-000051.md) | [9.4](/filings/0001517022-25-000046.md) | [12.5 d](/filings/0001517022-26-000020.md) | [12.3](/filings/0001517022-26-000039.md) | [10.4](/filings/0001517022-26-000051.md) |
| Research and development | $m | [13.3](/filings/0001628280-24-045979.md) | [9.9 d](/filings/0001517022-26-000020.md) | [9.7](/filings/0001628280-25-023460.md) | [7.6](/filings/0001628280-25-038600.md) | [8.5](/filings/0001517022-25-000046.md) | [11.8 d](/filings/0001517022-26-000020.md) | [9.8](/filings/0001517022-26-000039.md) | [11.0](/filings/0001517022-26-000051.md) | [14.9](/filings/0001517022-25-000046.md) | [26.6 d](/filings/0001517022-26-000020.md) | [14.8](/filings/0001517022-26-000039.md) | [14.1](/filings/0001517022-26-000051.md) |
| Selling, general and administrative | $m | [22.7](/filings/0001628280-24-045979.md) | [25.4 d](/filings/0001517022-26-000020.md) | [25.4](/filings/0001628280-25-023460.md) | [26.9](/filings/0001628280-25-038600.md) | [26.5](/filings/0001517022-25-000046.md) | [27.7 d](/filings/0001517022-26-000020.md) | [25.7](/filings/0001517022-26-000039.md) | [26.6](/filings/0001517022-26-000051.md) | [29.1](/filings/0001517022-25-000046.md) | [26.1 d](/filings/0001517022-26-000020.md) | [30.4](/filings/0001517022-26-000039.md) | [28.2](/filings/0001517022-26-000051.md) |
| Operating income | $m | [(13.0)](/filings/0001628280-24-045979.md) | [1.4 d](/filings/0001517022-26-000020.md) | [(14.9)](/filings/0001628280-25-023460.md) | [(8.7)](/filings/0001628280-25-038600.md) | [(12.5)](/filings/0001517022-25-000046.md) | [(14.3) d](/filings/0001517022-26-000020.md) | [13.5](/filings/0001517022-26-000039.md) | [14.1](/filings/0001517022-26-000051.md) | [4.4](/filings/0001517022-25-000046.md) | [(8.6) d](/filings/0001517022-26-000020.md) | [(4.7)](/filings/0001517022-26-000039.md) | [(6.3)](/filings/0001517022-26-000051.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001517022-25-000046.md) | [0.0 d](/filings/0001517022-26-000020.md) | [0.0](/filings/0001517022-26-000039.md) | [0.0](/filings/0001517022-26-000051.md) | [0.6](/filings/0001517022-25-000046.md) | [1.0 d](/filings/0001517022-26-000020.md) | [0.1](/filings/0001517022-26-000039.md) | [0.1](/filings/0001517022-26-000051.md) |
| Net income | $m | [(14.5)](/filings/0001628280-24-045979.md) | [0.6 d](/filings/0001517022-26-000020.md) | [(18.0)](/filings/0001517022-25-000046.md) | [(8.6)](/filings/0001517022-25-000046.md) | [(20.0)](/filings/0001517022-25-000046.md) | [(22.8) d](/filings/0001517022-26-000020.md) | [6.1](/filings/0001517022-26-000051.md) | [0.2](/filings/0001517022-26-000051.md) | [0.5](/filings/0001517022-25-000046.md) | [(12.2) d](/filings/0001517022-26-000020.md) | [(9.1)](/filings/0001517022-26-000051.md) | [(8.9)](/filings/0001517022-26-000051.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001628280-24-045979.md) | not reported | [(0.09)](/filings/0001628280-25-023460.md) | [(0.04)](/filings/0001628280-25-038600.md) | [(0.10)](/filings/0001517022-25-000046.md) | not reported | [0.03](/filings/0001517022-26-000039.md) | [0.00](/filings/0001517022-26-000051.md) | [0.00](/filings/0001517022-25-000046.md) | not reported | [(0.03)](/filings/0001517022-26-000039.md) | [(0.03)](/filings/0001517022-26-000051.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001628280-24-045979.md) | not reported | [(0.09)](/filings/0001628280-25-023460.md) | [(0.04)](/filings/0001628280-25-038600.md) | [(0.10)](/filings/0001517022-25-000046.md) | not reported | [0.03](/filings/0001517022-26-000039.md) | [0.00](/filings/0001517022-26-000051.md) | [0.00](/filings/0001517022-25-000046.md) | not reported | [(0.03)](/filings/0001517022-26-000039.md) | [(0.03)](/filings/0001517022-26-000051.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [46.5](/filings/0001628280-23-037557.md) | [42.9](/filings/0001517022-26-000020.md) | [42.0](/filings/0001628280-24-021945.md) | [39.5](/filings/0001628280-24-035879.md) | [34.0](/filings/0001628280-24-045979.md) | [51.9](/filings/0001517022-26-000020.md) | [113](/filings/0001628280-25-023460.md) | [137](/filings/0001628280-25-038600.md) | [166](/filings/0001517022-25-000046.md) | [185](/filings/0001517022-26-000051.md) | [163](/filings/0001517022-26-000039.md) | [156](/filings/0001517022-26-000051.md) |
| Current assets | $m | [110](/filings/0001628280-23-037557.md) | [118](/filings/0001628280-25-012470.md) | [113](/filings/0001628280-24-021945.md) | [112](/filings/0001628280-24-035879.md) | [100](/filings/0001628280-24-045979.md) | [114](/filings/0001517022-26-000020.md) | [204](/filings/0001628280-25-023460.md) | [235](/filings/0001628280-25-038600.md) | [258](/filings/0001517022-25-000046.md) | [253](/filings/0001517022-26-000051.md) | [243](/filings/0001517022-26-000039.md) | [230](/filings/0001517022-26-000051.md) |
| Total assets | $m | [235](/filings/0001628280-23-037557.md) | [242](/filings/0001628280-25-012470.md) | [225](/filings/0001628280-24-021945.md) | [220](/filings/0001628280-24-035879.md) | [207](/filings/0001628280-24-045979.md) | [221](/filings/0001517022-26-000020.md) | [310](/filings/0001628280-25-023460.md) | [346](/filings/0001628280-25-038600.md) | [364](/filings/0001517022-25-000046.md) | [377](/filings/0001517022-26-000051.md) | [363](/filings/0001517022-26-000039.md) | [350](/filings/0001517022-26-000051.md) |
| Current liabilities | $m | [79.7](/filings/0001628280-23-037557.md) | [99.9](/filings/0001628280-25-012470.md) | [66.5](/filings/0001628280-24-021945.md) | [107](/filings/0001628280-24-035879.md) | [65.7](/filings/0001628280-24-045979.md) | [80.9](/filings/0001517022-26-000020.md) | [91.2](/filings/0001628280-25-023460.md) | [119](/filings/0001628280-25-038600.md) | [133](/filings/0001517022-25-000046.md) | [163](/filings/0001517022-26-000051.md) | [174](/filings/0001517022-26-000039.md) | [161](/filings/0001517022-26-000051.md) |
| Total liabilities | $m | [274](/filings/0001628280-23-037557.md) | [272](/filings/0001628280-25-012470.md) | [253](/filings/0001628280-24-021945.md) | [254](/filings/0001628280-24-035879.md) | [258](/filings/0001628280-24-045979.md) | [270](/filings/0001517022-26-000020.md) | [286](/filings/0001628280-25-023460.md) | [316](/filings/0001628280-25-038600.md) | [323](/filings/0001517022-25-000046.md) | [344](/filings/0001517022-26-000051.md) | [335](/filings/0001517022-26-000039.md) | [325](/filings/0001517022-26-000051.md) |
| Long-term debt | $m | [34.6](/filings/0001628280-23-037557.md) | [17.2](/filings/0001628280-25-012470.md) | [30.1](/filings/0001628280-24-021945.md) | [38.0](/filings/0001628280-24-035879.md) | [38.4](/filings/0001628280-24-045979.md) | [38.7](/filings/0001517022-26-000020.md) | [46.5](/filings/0001628280-25-023460.md) | [47.1](/filings/0001628280-25-038600.md) | [47.6](/filings/0001517022-25-000046.md) | [48.3](/filings/0001517022-26-000051.md) | [36.4](/filings/0001517022-26-000039.md) | [24.8](/filings/0001517022-26-000051.md) |
| Current portion of debt | $m | [8.0](/filings/0001628280-23-037557.md) | [17.5](/filings/0001628280-25-012470.md) | [0.0](/filings/0001628280-24-021945.md) | [0.0](/filings/0001628280-24-035879.md) | [0.0](/filings/0001628280-24-045979.md) | [0.0](/filings/0001628280-25-012470.md) | not reported | not reported | not reported | [0.0](/filings/0001517022-26-000051.md) | [12.5](/filings/0001517022-26-000039.md) | [24.8](/filings/0001517022-26-000051.md) |
| Shareholders' equity | $m | [(39.4)](/filings/0001628280-24-045979.md) | [(30.6)](/filings/0001517022-26-000020.md) | [(27.3)](/filings/0001517022-25-000046.md) | [(33.8)](/filings/0001517022-25-000046.md) | [(50.4)](/filings/0001517022-25-000046.md) | [(49.2)](/filings/0001517022-26-000051.md) | [24.6](/filings/0001517022-26-000051.md) | [29.2](/filings/0001517022-26-000051.md) | [41.6](/filings/0001517022-25-000046.md) | [32.6](/filings/0001517022-26-000051.md) | [27.4](/filings/0001517022-26-000051.md) | [25.0](/filings/0001517022-26-000051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.2) d](/filings/0001628280-24-045979.md) | [(2.3) d](/filings/0001517022-26-000020.md) | [(19.4)](/filings/0001628280-25-023460.md) | [(10.1) d](/filings/0001628280-25-038600.md) | [(6.7) d](/filings/0001517022-25-000046.md) | [(4.5) d](/filings/0001517022-26-000020.md) | [(13.6)](/filings/0001517022-26-000039.md) | [22.3 d](/filings/0001517022-26-000051.md) | [28.1 d](/filings/0001517022-25-000046.md) | [31.1 d](/filings/0001517022-26-000020.md) | [(21.2)](/filings/0001517022-26-000039.md) | [3.5 d](/filings/0001517022-26-000051.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-045979.md) | [0.0 d](/filings/0001517022-26-000020.md) | [0.0](/filings/0001628280-25-023460.md) | [0.0 d](/filings/0001628280-25-038600.md) | [0.0 d](/filings/0001517022-25-000046.md) | [0.0 d](/filings/0001517022-26-000020.md) | [0.0](/filings/0001517022-26-000039.md) | [0.1 d](/filings/0001517022-26-000051.md) | [0.1 d](/filings/0001517022-25-000046.md) | [0.1 d](/filings/0001517022-26-000020.md) | [0.1](/filings/0001517022-26-000039.md) | [1.1 d](/filings/0001517022-26-000051.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [184](/filings/0001628280-23-037557.md) | [185](/filings/0001628280-24-021945.md) | [187](/filings/0001628280-24-035879.md) | [188](/filings/0001628280-24-045979.md) | [205](/filings/0001628280-25-023460.md) | [210](/filings/0001628280-25-038600.md) | [210](/filings/0001517022-25-000046.md) | [242](/filings/0001517022-26-000039.md) | [271](/filings/0001517022-26-000051.md) | [274](/filings/0001517022-25-000046.md) | [267](/filings/0001517022-26-000039.md) | [270](/filings/0001517022-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 277,106,245 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001517022-26-000051.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.